Le Lézard
Classified in: Health
Subject: HEALTH

Alzheimer Society of Canada invests nearly $6 million to support innovative dementia research


TORONTO, July 20, 2023 (GLOBE NEWSWIRE) -- The Alzheimer Society of Canada in collaboration with Brain Canada Foundation, Canadian Institutes of Health Research ? Institute of Aging, and Research Manitoba are investing $5,989,000 in 44 dementia researchers as part of its annual research competition. The Alzheimer Society Research Program (ASRP) is one of Canada's most innovative hubs for dementia research, helping the best and brightest minds in the field accelerate their work ? from ideas to impact.

The ASRP-funded projects fall under eight funding priorities, which are all aimed at encouraging researchers to explore new ways to advance our knowledge and understanding of dementia. The research areas include care, cause, diagnosis, epidemiology, risk, therapy, translational and treatment. To read the full list of researchers and projects funded, visit alzheimer.ca/fundingresults.

This year, overall funding has increased to nearly $6 million from $3.5 million in 2022. "We are setting the standard for dementia research in this country," says Christopher Barry, Chief Executive Officer, Alzheimer Society of Canada. "After decades of underfunding, we've focused on investing in the next generation of researchers, as well as increasing the overall number of researchers we're funding."

Each application was reviewed by experts in the field of dementia research, as well as volunteers with lived experience of dementia, to ensure that the projects receiving funding have the potential to truly make a difference for people living with dementia and caregivers.

The ASRP is funded by generous donors and by funding partners, including Brain Canada Foundation, Canadian Institutes of Health Research ? Institute of Aging, and Research Manitoba. "Through our partnerships with these incredible organizations, we've nearly doubled our total research investment this year," says Christopher Barry, Chief Executive Officer, "It's by working together and prioritizing dementia that we are truly able to make a difference, nationwide."

Unfortunately, each year, promising work goes unfunded. More investment and funding for dementia research is needed so that we don't leave potentially life-changing ideas unexplored. You can give directly to support dementia research in Canada by visiting alzheimer.ca/donate.

Learn more about the Alzheimer Society Research Program and the latest funding results by visiting alzheimer.ca/asrp2023.

Background

Alberta (AB)4
British Columbia (BC)10
Manitoba (MB)2
Newfoundland & Labrador (NL)1
Ontario (ON)12
Quebec (QC)15


For more information, please contact:

James Harrison, Communications Manager
Alzheimer Society of Canada
[email protected]
1-800-616-8816 ext. 2955



These press releases may also interest you

at 07:15
International medical imaging IT and Cybersecurity company Sectra's (STO: SECT B) digital pathology solution together with Leica Biosystems, Imaging, Inc.'s Aperio GT 450 DX have received a 510(k) clearance by the US Food & Drug Administration (FDA)....

at 07:11
Author C.A. Blake was 24 years old when her brother, Steve, committed suicide. She struggled with the feeling she wouldn't survive the pain of it. Growing up in a time where little to no coping skills were taught or offered, she traveled the path of...

at 07:05
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor...

at 07:05
Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective...

at 07:05
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger...

at 07:05
bit.bio, the company coding human cells for novel cures, and a pioneer in the field of synthetic biology, today announces it will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio founder...



News published on and distributed by: